News Sentiment

KOD sentiment intelligence

Kodiak Sciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 41.31 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+7.2% over one week, +21.3% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Dow, S&P 500, Nasdaq Futures Rise After Trump’s 10-Day Iran Pause: Why META, DJT, U, KOD, MDGL Are Trending After-Hours

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction 7.2% Price confirming higher
Trend fit Trend active 21.3% over four weeks
Fair value 281.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 40
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Stock Titan 10
TradingView 8
TradingKey 4
www.marketscreener.com 3
timothysykes.com 2
ChartMill 2
Sahm 2

Event Lens

What the news is about

Classified themes
Market update 35
Earnings 19
Regulatory and legal 2
Analyst action 2
Balance sheet 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 60
Market source Direct company coverage

Kodiak Sciences (KOD) Is Down 15.4% After Strong Zenkuda GLOW2 Data And Accelerated Filing Plans

Kodiak Sciences (KOD) experienced a 15.4% stock drop despite presenting strong Phase III GLOW2 data for its ophthalmology candidate Zenkuda and announcing accelerated regulatory filing plans. The company's investment narrative hinges on Zenkuda and its ABC platform transforming i

Tone
Negative 36/100
Event
Regulatory and legal
Published
07 Jun 2026 05:09
Source
Market source
Sahm Direct company coverage

Kodiak Sciences Zenkuda Trial Win Puts Cash Needs And Growth In Focus

Kodiak Sciences reported positive phase III results for its drug candidate Zenkuda in diabetic retinopathy, accelerating regulatory submissions. This success could make Zenkuda Kodiak's first commercial product, but the company faces challenges with less than one year of cash run

Tone
Positive 72/100
Event
Earnings
Published
06 Jun 2026 19:10
Source
Sahm
Investing.com Nigeria Direct company coverage

Kodiak Sciences CFO John Borgeson sold $1.02 million in NASDAQ:KOD shares

Kodiak Sciences CFO John Borgeson sold 30,000 shares of Kodiak Sciences Inc. (NASDAQ:KOD) common stock for a total of $1.02 million on June 4, 2026, through a pre-planned trading arrangement. Prior to the sale, Borgeson exercised options to acquire the same number of shares at a

Tone
Neutral 50/100
Event
Market update
Published
06 Jun 2026 16:39
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Kodiak (KOD) CFO sells 30,000 shares under 10b5-1 trading plan

Kodiak Sciences Inc. CFO, John A. Borgeson, executed an exercise-and-sell transaction involving 30,000 common shares. He acquired these shares by exercising stock options at $1.04 per share and then sold them in open-market transactions at weighted-average prices of $34.01 and $3

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 21:39
Source
Stock Titan
ChartMill Direct company coverage

KOD News | KODIAK SCIENCES INC (NASDAQ:KOD)

This article provides news and stock information for Kodiak Sciences Inc. (NASDAQ: KOD). It highlights a 35% stock rise over three months and announces Kodiak Sciences' participation in the 2026 Jefferies Global Healthcare Conference.

Tone
Positive 70/100
Event
Market update
Published
05 Jun 2026 17:09
Source
ChartMill